BiotechTube
Home/Pipeline/NP104G

NP104G

Oncology (unspecified)

PreclinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Preclinical
Status
Active
Company
Nostopharma

About Nostopharma

Nostopharma is a preclinical-stage biotech leveraging drug repurposing to develop small molecule therapies for heterotopic ossification (HO) and other conditions. Its lead strategy involves using approved Hedgehog inhibitors to prevent abnormal bone growth following trauma, supported by positive mouse model data. The company maintains a balanced portfolio with programs in oncology and regenerative medicine, emphasizing clear biomarkers and partnership-ready paths for de-risked execution.

View full company profile

Therapeutic Areas

Orthopedic TraumaRegenerative MedicineOncologyImmunology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a
DDX3 Inhibitor (Oncology)Lead Discovery SienaDiscovery
Roginolisib (IOA-244)iOncturaPhase 2